Table 3.
Univariate risk analysis of features in the nivolumab efficacy deep learning model and survival time.
| miRNA | coef | HR | HR lower 95% | HR upper 95% | p |
|---|---|---|---|---|---|
| hsa-let-7c | -0.1176 | 0.8891 | 0.8195 | 0.9646 | *0.0047 |
| hsa-let-7g | -0.1714 | 0.8425 | 0.7206 | 0.9851 | *0.0317 |
| hsa-mir-146a | -0.0852 | 0.9184 | 0.8437 | 0.9997 | *0.0491 |
| hsa-mir-22 | 0.1955 | 1.2159 | 1.0295 | 1.4361 | *0.0213 |
| hsa-mir-23a | 0.1695 | 1.1847 | 1.0204 | 1.3754 | *0.0261 |
| hsa-mir-30b | -0.1295 | 0.8786 | 0.7992 | 0.9658 | *0.0074 |
| hsa-mir-30e | -0.1731 | 0.8411 | 0.7140 | 0.9907 | *0.0383 |